Background Supplementation of citicoline (CDP-choline), a naturally occurring mononucleotide, has shown beneficial effects on memory function and behavior in populations with a wide range of impairments. However, few studies have investigated its effect in healthy older populations. Objective The objective of this study was to investigate the effects of citicoline (Cognizin®), on memory in healthy elderly populations with age-associated memory impairment (AAMI). Methods A total of 100 healthy men and women aged between 50 and 85 y with AAMI participated in this randomized, double-blind, placebo-controlled trial. Participants were randomized to receive placebo (n = 51) or citicoline (n = 49; 500 mg/d) for 12 wk. Memory function was assessed at baseline and end of the intervention (12 wk) using computerized tests (Cambridge Brain Sciences, Ontario, Canada). Safety measurements included adverse events query, body weight, blood pressure, and hematology and metabolic panel. Intent-to-treat analysis was conducted using ANCOVA for the primary and secondary outcome variables with Bonferroni correction for multiple comparisons. Results A total of 99 out of 100 participants completed the study in its entirety. After the 12-wk intervention, participants supplemented with citicoline showed significantly greater improvements in secondary outcomes of episodic memory (assessed by the Paired Associate test), compared with those on placebo (mean: 0.15 vs. 0.06, respectively, P = 0.0025). Composite memory (secondary outcome), calculated using the scores of 4 memory tests, also significantly improved to a greater extent following citicoline supplementation (mean: 3.78) compared with placebo (mean: 0.72, P = 0.0052). Conclusions Dietary supplementation of citicoline for 12 wk improved overall memory performance, especially episodic memory, in healthy older males and females with AAMI. The findings suggest that regular consumption of citicoline may be safe and potentially beneficial against memory loss due to aging. This trial was registered at clinicaltrials.gov as NCT03369925.
Adolescent males receiving 28 days of Cognizin® citicoline showed improved attention and psychomotor speed and reduced impulsivity compared to adolescent males who received placebo.
Objectives Subtle deficits in memory in healthy elderly adults are considered to be a normal consequence of aging [i.e., age-associated memory impairment (AAMI)]. The prevalence of cognitive impairment without dementia in the elderly is estimated at 5.4 million, and every year roughly 12% of these individuals go on to develop dementia. Supplementation of citicoline (CDP-choline), a naturally occurring mononucleotide, has shown beneficial effects on memory function and behavior in populations with a wide range of impairments. Unfortunately, few studies have investigated the effects of citicoline supplementation on memory in healthy elderly adults with memory loss due to aging. Thus, the objective of this study was to investigate the effects of Cognizin®, a citicoline supplement, on memory in healthy elderly populations with AAMI. Methods A total of 100 healthy men and women between 50 to 85 years of age with AAMI participated in this randomized, double-blind, placebo-controlled trial. Subjects were randomized to receive placebo (n = 51) or Cognizin® (n = 49; 500 mg/day) for 12 weeks. Memory functions were assessed at baseline and end of the intervention (12 weeks) using computerized tests (Cambridge Brain Sciences, Ontario, Canada). Safety measurements included adverse events query, hematology and clinical chemistry. Results A total of 99 out of 100 subjects completed the study in its entirety. After the 12 week intervention, subjects supplemented with Cognizin® showed significantly greater improvements in episodic memory (assessed by the Paired Associate test) compared to those on placebo. Scores for composite memory, calculated using the scores of four memory tests (Spatial Span, Monkey Ladder, Paired Associate, and Digit Span) also improved to a greater extent following Cognizin® supplementation compared to placebo. There were no adverse events related to a study product and hematology and clinical chemistry were stable throughout the intervention. Conclusions Dietary supplement of Cognizin® for 12 weeks improved overall memory performance, especially episodic memory, in healthy males and females with AAMI. The findings suggest that regular consumption of Cognizin® may be safe and potentially beneficial against memory loss due to aging. Funding Sources Kyowa Hakko Bio Co., Ltd.
No abstract
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.